DRTS: First glioblastoma patient treated and pivotal U.S. trials signal major clinical and commercial momentum

WSW, NY, December 10th, 2025, FinanceWire

The first use of Alpha DaRT in a human brain tumor sets a new clinical precedent and may signal a company on the verge of broader recognition.

Alpha Tau Medical , a company still flying below most investors’ radars, may have just reached one of the most important moments in its history: the first use of its Alpha DaRT therapy inside a human brain tumor. The procedure, performed at The Ohio State University’s James Cancer Hospital, marks the beginning of the company’s U.S. pilot study in recurrent glioblastoma multiforme (GBM) - a fast-moving, highly aggressive cancer with few effective treatment options.

This is the first time Alpha DaRT has ever been delivered into the brain, one of the most technically demanding environments in oncology. Using a dedicated intracranial delivery system compatible with standard neurosurgical navigation tools, the clinical team achieved more than 95% tumor coverage. The study will treat up to ten patients who have exhausted most available therapies.

Why This Moment Matters

A successful first treatment in the brain signals a potential shift in how the Alpha DaRT platform is viewed. Until now the therapy has been associated mostly with superficial and cutaneous tumors. Demonstrating feasibility in a deep and sensitive anatomical location broadens the platform’s potential considerably. Therapies that prove adaptability to challenging indications often receive a reassessment from the market, since they move from being indication-specific tools to technologies with broader multi-tumor relevance.

Alpha DaRT’s underlying design also supports this expanded potential. The therapy delivers high-energy alpha particles through a localized implant, allowing a strong tumor-killing effect while limiting radiation to surrounding healthy tissue. In the brain, where collateral damage carries heavy consequences, this precision can become a significant competitive advantage. If early feasibility continues to hold through additional patients, investors may begin viewing Alpha Tau as a more versatile radiotherapeutic platform than previously recognized.

A Small Market in a Big-Valuation Category

Despite this progress, Alpha Tau’s market capitalization sits at roughly $363 million (as of December 9, 2025). This stands out in a sector where radiotherapeutic companies with early-stage programs can reach valuations in the billions. The scale of the potential disconnect becomes clearer when compared with recent activity in the space. Eli Lilly acquired POINT Biopharma for approximately $1.4 billion, signaling a strong appetite for platforms capable of delivering targeted radiation. Several other radiopharma companies have commanded similarly high valuations based on mechanisms that often appear more complex and operationally demanding than Alpha Tau’s localized, device-based system.

The difference is that most radiotherapeutic competitors rely on systemic radioligand therapies - complex molecules that circulate through the body, require specialized supply chains, and demand careful toxicity management. Alpha Tau avoids many of these challenges by taking a purely localized approach, reducing the infrastructure and manufacturing burden that typically accompanies systemic radiopharmaceutical deployment.

Momentum Building Beneath the Surface

Beyond the GBM milestone, Alpha Tau has been expanding its clinical footprint across the United States, Europe and Israel. The company has continued to develop additional tumor indications and has been investing in manufacturing capacity to support future commercial scale. Regulatory positioning has strengthened through both Breakthrough Device Designation and inclusion in the FDA Total Product Life Cycle Advisory Program. These designations can streamline regulatory interactions and reduce uncertainty around development timelines, yet they have not significantly shifted investor perception so far.

The company’s continued focus on engineering specialized delivery systems also supports its long-term growth prospects. The intracranial system used in the GBM procedure is only one example of how Alpha Tau is working to adapt Alpha DaRT to a broader range of tumor environments. Platform companies that can extend their core technology into multiple indications often experience significant value creation once the market recognizes the breadth of their potential.

A Sector That Is Heating Up

Radiotherapeutics in general have become one of the more active categories in oncology investment in recent years. Strategic buyers and institutional investors have increased their focus on this area due to strong clinical results and rising demand for targeted cancer therapies. While much of the attention has been directed toward radiopharmaceutical pipelines, Alpha Tau’s device-based approach offers a differentiated alternative. This positions the company within the same high-growth category while avoiding many of the structural challenges faced by systemic radiotherapy manufacturers.

The Bottom Line

Alpha Tau’s first use of Alpha DaRT in a brain tumor is more than a clinical success. It expands the perceived scope of the technology, places the company within one of the most sought-after areas of oncology innovation, and highlights a valuation that appears low relative to the potential opportunity. As additional patients are treated and more data emerge, Alpha Tau may attract the kind of attention that has driven substantial revaluations in other radiotherapeutic companies. For investors watching the next wave of precision oncology platforms, Alpha Tau’s recent progress is making it a name that may be worth watching closely.

Recent News Highlights from Alpha Tau Medical

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer

Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. The content above is a form of paid promotional content and advertising. Wall Street Wire receives cash compensation from Oramed Pharmaceuticals Inc for promotional media services provided on an ongoing subscription basis to to Alpha Tau Medical Ltd. This content is for informational purposes only and does not constitute financial or investment advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. Market size figures or other estimates referenced in this article are quoted from publicly available sources; we do not independently verify or endorse them, and additional figures or estimates may exist. This article should not be considered an official communication of the issuer.

Contact

Wall Street Wire

coverage@wallstwire.ai